Breakdown | ||
Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|
Income Statement | Total Revenue | |
0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | 0.00 | EBIT |
― | -13.72M | -4.62M | EBITDA |
188.71K | -953.08K | -28.75K | Net Income Common Stockholders |
-67.33K | 4.41M | -15.60M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |
8.84K | 129.19K | 7.12M | Total Assets |
17.04M | 357.14M | 7.66M | Total Debt |
1.63M | 40.01M | 23.48M | Net Debt |
1.62M | 39.88M | 16.36M | Total Liabilities |
17.73M | 15.06M | 24.15M | Stockholders Equity |
-695.80K | 342.08M | -16.49M |
Cash Flow | Free Cash Flow | |
-1.38M | -694.44K | -5.38M | Operating Cash Flow |
-1.38M | -215.40K | -5.27M | Investing Cash Flow |
342.92M | ― | -109.73K | Financing Cash Flow |
-341.66M | 7.50K | 12.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | $12.61B | 9.79 | 7.95% | 16985.69% | 12.77% | -3.98% | |
52 Neutral | $208.77M | ― | -85.03% | ― | -15.39% | 19.42% | |
51 Neutral | $237.58M | ― | -222.36% | ― | -86.28% | -476.70% | |
48 Neutral | $216.37M | ― | -173.41% | ― | ― | 22.99% | |
41 Neutral | $246.65M | ― | -174.85% | ― | ― | -71.53% | |
40 Underperform | $199.20M | ― | -43.76% | ― | ― | ― | |
33 Underperform | $185.73M | ― | -124.74% | ― | ― | -20.39% |
On April 17, 2025, Tevogen Bio Holdings Inc. announced a Master Services and Facilities Agreement with CD 8 Technology Services LLC to access specialized manufacturing facilities for cell therapy production. This agreement is a strategic move to enhance Tevogen’s in-house production capabilities, aligning with its long-term strategy to accelerate development timelines, maintain operational agility, and control costs, thereby overcoming significant capital barriers typically faced in building GMP capabilities.
Spark’s Take on TVGN Stock
According to Spark, TipRanks’ AI Analyst, TVGN is a Underperform.
Tevogen Bio Holdings faces significant financial challenges, with operational losses and high leverage being key risks. Technical analysis indicates a bearish trend, and valuation metrics reflect the speculative nature typical of biotech firms in early development stages. However, recent funding announcements provide a positive outlook for strategic advancements, offering some mitigation to the financial risks.
To see Spark’s full report on TVGN stock, click here.